NASDAQ$ABCL
AbCellera Biologics Inc. · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
AbCellera Biologics reported higher revenue in Q2 2025 driven by licensing income while advancing its internal pipeline.
For the three months ended June 30, 2025, AbCellera generated total revenue of $17.1 million, up significantly from the prior year due to licensing revenue. The company posted a net loss of $34.7 million and an operating loss of $49.6 million. Cash and cash equivalents stood at $92.4 million with total assets of $1.4 billion at quarter end.
- Total revenue reached $17.1 million, more than double the $7.3 million reported in Q2 2024, primarily due to $10.4 million in licensing revenue.
- Net loss improved to $34.7 million from $36.9 million in the prior-year quarter.
- Research fees contributed $6.6 million while milestone payments were zero in the quarter.
- Cash and cash equivalents were $92.4 million and total assets reached $1.4 billion as of June 30, 2025.
Headline financials
Revenue & EPS history
AbCellera · Revenue · Quarterly
$17.1M
Revenue by segment
AbCellera · $17.1M total across 2 segments · Q2 2025
- Licensing revenue$10.4M—61.1%
- Research fees$6.64M—38.9%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
-0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.2%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+17.1%
Q2 2021
Best reaction
-13.9%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +0.2% | -21.8% | -2.9% | |
| Q4 2025 | -1.5% | +18.6% | +1.6% | |
| Q3 2025 | -13.9% | -12.4% | -21.4% | |
| Q1 2025 | +1.0% | +2.0% | +21.4% | |
| Q4 2024 | -11.3% | -18.2% | -20.9% | |
| Q3 2024 | -0.4% | -1.1% | +6.2% | |
| Q2 2024 | -4.7% | -2.9% | -12.0% | |
| Q1 2024 | -6.6% | -6.8% | -8.0% | |
| Q4 2023 | -9.9% | -8.8% | -11.8% | |
| Q3 2023 | +14.1% | +6.8% | +17.2% | |
| Q2 2023 | -13.0% | -15.1% | -19.5% | |
| Q1 2023 | -9.1% | -14.1% | +3.0% | |
| Q4 2022 | -8.3% | -12.7% | -23.8% | |
| Q3 2022 | -1.7% | +13.1% | -7.2% | |
| Q2 2022 | +13.4% | +16.3% | -3.9% | |
| Q1 2022 | -12.0% | +11.2% | +29.1% | |
| Q4 2019 | +8.1% | +9.4% | +15.5% | |
| Q4 2021 | +8.1% | +9.4% | +15.5% | |
| Q3 2020 | -7.8% | -2.0% | -5.1% | |
| Q2 2018 | +16.3% | +10.3% | +25.0% | |
| Q2 2021 | +17.1% | +8.6% | +24.3% | |
| Q1 2018 | +0.1% | -5.2% | -24.1% | |
| Q1 2021 | +3.4% | +7.4% | -15.7% | |
| Q4 2018 | +7.8% | +24.1% | +21.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro